The Fifth INTEnsive pReventing Secondary Injury in Acute Cerebral Haemorrhage Trial Within ACT-GLOBAL

PHASE3RecruitingINTERVENTIONAL
Enrollment

2,000

Participants

Timeline

Start Date

February 27, 2025

Primary Completion Date

January 31, 2028

Study Completion Date

January 31, 2028

Conditions
Intracerebral HemorrhageSpontaneous Intracerebral HemorrhageSupratentorial Intracerebral HaemorrhageAcute Intracerebral HaemorrhageAcute Stroke
Interventions
DRUG

Colchicine 0.5 mg

The intervention group will receive 0.5mg of oral colchicine daily as soon as possible after randomization, to continue for 30 days.

DRUG

Deferoxamine Mesylate

The intervention group will receive deferoxamine mesylate at a dose of 32mg/kg/day via intravenous infusion immediately (within 1 hour) and continued for 2 consecutive days

OTHER

Control (Standard treatment)

The group will not receive deferoxamine mesylate or colchicine

Trial Locations (2)

2050

NOT_YET_RECRUITING

Royal Prince Alfred Hospital, Sydney

610041

RECRUITING

West China Hospital of Sichuan University, Chengdu

All Listed Sponsors
collaborator

University of Calgary

OTHER

lead

The George Institute

OTHER